Table 3.
Characteristics of the 103 journal articles on phase I oncology trials which were evaluated for meeting quality assessment measures in the newly designed phase I trial checklist
| N(%) | |
|---|---|
| Journal | |
| Clin Cancer Res | 18 (17.5%) |
| Cancer Chemother Pharmacol | 14 (13.6%) |
| J Clin Oncol | 13 (12.6%) |
| Br J Cancer | 8 (7.8%) |
| Ann Oncol | 6 (5.8%) |
| Invest New Drugs | 6 (5.8%) |
| Oncology | 6 (5.8%) |
| Cancer | 5 (4.9%) |
| Anticancer Res | 4 (3.9%) |
| Cancer Invest | 4 (3.9%) |
| Chemotherapy | 4 (3.9%) |
| Eur J Cancer | 4 (3.9%) |
| Anticancer Drugs | 3 (2.9%) |
| Int J Radiat Oncol Biol Phys | 3 (2.9%) |
| Jpn J Clin Oncol | 3 (2.9%) |
| Gynecol Oncol | 2 (1.9%) |
| Geographic region | |
| Asia and Oceanic ocean | 18 (17.5%) |
| Europe | 41 (39.8%) |
| North America | 44 (42.7%) |
| Trial | |
| Sample size: median (Q1–Q3) | 25 (18.5–33.5) |
| Number of dose levels: median (Q1–Q3) | 5 (4–6) |
| Treatment type | |
| Monotherapy | 40 (38.8%) |
| Combination | 63 (61.2%) |